High Prescription Rate of Medications With Rifampin Drug-drug Interactions in Patients With Diabetic Foot Osteomyelitis: Should Rifabutin Be Included in Clinical Trials for Adjunctive Therapy?

Autor:	Mallarino-Haeger C; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Watson A; Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA., Mahgoub U; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA., Francis L; Medical College of Georgia, Augusta University, Augusta, Georgia, USA., Heydari M; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA., Choudhary M; Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA., Garcia-Toca M; Division of Vascular Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.; Grady Health System, Atlanta, Georgia, USA., Patel M; Grady Health System, Atlanta, Georgia, USA., Kempker RR; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Grady Health System, Atlanta, Georgia, USA., Fayfman M; Grady Health System, Atlanta, Georgia, USA.; Division of Endocrinology, Metabolism, and Lipids, Emory University School of Medicine, Atlanta, Georgia, USA., Schechter MC; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Grady Health System, Atlanta, Georgia, USA.
Jazyk:	angličtina
Zdroj:	Open forum infectious diseases [Open Forum Infect Dis] 2024 Oct 11; Vol. 11 (11), pp. ofae582. Date of Electronic Publication: 2024 Oct 11 (Print Publication: 2024).
DOI:	10.1093/ofid/ofae582
Abstrakt:	Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug-drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug-drug interactions, would be easier to implement in practice. Competing Interests: Potential conflicts of interest. All authors: No reported conflicts. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu